ArriVent BioPharma, Inc.

NasdaqGM:AVBP Stock Report

Market Cap: US$1.2b

ArriVent BioPharma Valuation

Is AVBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of AVBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: AVBP ($27.64) is trading below our estimate of future cash flow value ($178.32)

Significantly Below Future Cash Flow Value: AVBP is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVBP?

Key metric: As AVBP is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AVBP. This is calculated by dividing AVBP's market cap by their current book value.
What is AVBP's PB Ratio?
PB Ratio4x
BookUS$307.22m
Market CapUS$1.18b

Price to Book Ratio vs Peers

How does AVBP's PB Ratio compare to its peers?

The above table shows the PB ratio for AVBP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average50.4x
INBX Inhibrx Biosciences
152x48.89%US$1.1b
MPLT MapLight Therapeutics
2.6x-10.64%US$1.1b
GERN Geron
5x62.53%US$1.1b
NNNN Anbio Biotechnology
42xn/aUS$1.3b
AVBP ArriVent BioPharma
4x48.08%US$1.2b

Price-To-Book vs Peers: AVBP is good value based on its Price-To-Book Ratio (4x) compared to the peer average (50.4x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does AVBP's PB Ratio compare vs other companies in the US Biotechs Industry?

54 CompaniesPrice / BookEstimated GrowthMarket Cap
ENLV Enlivex
0.1x-74.01%US$198.97m
CNTN Canton Strategic Holdings
0.5xn/aUS$187.53m
ACET Adicet Bio
0.5x26.03%US$68.26m
MGX Metagenomi Therapeutics
0.3x-9.03%US$52.67m
AVBP 4.0xIndustry Avg. 2.3xNo. of Companies82PB0246810+
54 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: AVBP is expensive based on its Price-To-Book Ratio (4x) compared to the US Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is AVBP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVBP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AVBP's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AVBP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$27.64
US$41.10
+48.71%
16.03%US$50.00US$25.25n/a12
Apr ’27US$24.22
US$41.10
+69.71%
16.03%US$50.00US$25.25n/a12
Mar ’27US$22.97
US$40.25
+75.25%
11.75%US$45.00US$31.00n/a11
Feb ’27US$22.49
US$40.23
+78.89%
11.25%US$45.00US$31.00n/a12
Jan ’27US$20.12
US$40.23
+99.97%
11.25%US$45.00US$31.00n/a12
Dec ’26US$22.52
US$39.70
+76.29%
11.82%US$45.00US$31.00n/a10
Nov ’26US$18.73
US$39.56
+111.19%
11.44%US$45.00US$33.00n/a9
Oct ’26US$18.46
US$39.56
+114.28%
11.44%US$45.00US$33.00n/a9
Sep ’26US$19.12
US$39.56
+106.88%
11.44%US$45.00US$33.00n/a9
Aug ’26US$18.66
US$40.22
+115.55%
9.36%US$45.00US$33.00n/a9
Jul ’26US$20.89
US$41.13
+96.86%
7.13%US$45.00US$37.00n/a8
Jun ’26US$21.25
US$39.50
+85.88%
6.58%US$45.00US$36.00n/a8
May ’26US$21.08
US$39.29
+86.36%
7.03%US$45.00US$36.00n/a7
Apr ’26US$18.03
US$39.29
+117.89%
7.03%US$45.00US$36.00US$24.227
Mar ’26US$23.61
US$38.60
+63.49%
4.21%US$41.00US$36.00US$22.975
Feb ’26US$28.54
US$38.60
+35.25%
4.21%US$41.00US$36.00US$22.495
Jan ’26US$26.64
US$38.00
+42.64%
4.99%US$41.00US$36.00US$20.125
Dec ’25US$29.96
US$38.33
+27.95%
4.92%US$41.00US$36.00US$22.526
Nov ’25US$30.78
US$38.00
+23.46%
4.56%US$41.00US$36.00US$18.736
Oct ’25US$23.79
US$38.00
+59.73%
4.56%US$41.00US$36.00US$18.466
Sep ’25US$26.73
US$31.83
+19.09%
8.39%US$35.00US$28.00US$19.126
Aug ’25US$21.50
US$31.00
+44.19%
11.93%US$35.00US$25.00US$18.666
Jul ’25US$18.15
US$30.20
+66.39%
11.74%US$35.00US$25.00US$20.895
Jun ’25US$19.41
US$30.20
+55.59%
11.74%US$35.00US$25.00US$21.255
May ’25US$16.69
US$30.20
+80.95%
11.74%US$35.00US$25.00US$21.085
Apr ’25US$18.31
US$31.50
+72.04%
8.55%US$35.00US$28.00US$18.034
US$41.1
Fair Value
32.8% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/14 23:14
End of Day Share Price 2026/04/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ArriVent BioPharma, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.
Suranjit MukherjeeBTIG